Strong Financial Performance Driven by Expansion in Diagnostic Imaging, AI-
Powered Healthcare Solutions, and International Market Growth

Mumbai, India — June 2026: Fischer Medical Ventures Limited (BSE: 524743 | ISIN: INE771F01041), a leading healthcare technology and diagnostic imaging company engaged in the processing, manufacturing, and trading of laboratory-grade chemicals and advanced medical technologies, announced its audited financial results for FY26, reporting exceptional growth across all key financial indicators.

The company recorded a 186% year-on-year increase in Total Income, reaching ₹32,088.93 crore compared to ₹11,219.07 crore in FY25. Revenue rose by 179% YoY to ₹30,857.56 crore, while EBITDA surged by an impressive 1,052% YoY to ₹5,539.71 crore. Net Profit climbed 2,489% YoY to ₹3,107.38 crore, reflecting improved operational efficiencies, enhanced product realization, and growing market acceptance of Fischer’s healthcare technologies.

Financial Highlights (Consolidated)

H1 FY26 Performance

Strategic Growth Across India and International Markets

During FY26, Fischer Medical Ventures significantly strengthened its position in the global diagnostic imaging and healthcare technology ecosystem through strategic partnerships, product innovation, and geographic expansion.

Major Milestones During FY26

AI-Powered X-Ray Expansion in India and Indonesia

The company launched several new X-ray initiatives across Asia, including a landmark partnership with the City of Jember, Indonesia, to deploy AI-powered portable X-ray systems. The initiative supports the “TB Free Jember by 2026” mission and broader tuberculosis elimination efforts targeted for 2030, representing projects valued at approximately USD 10 million.

Fischer also secured complete regulatory licensing in Indonesia, enabling participation in national End-TB handheld X-ray government tenders.

In India, the company received a major order from the Tamil Nadu Animal Husbandry Department for the supply and installation of 65 Digital Radiography Units, further strengthening its domestic imaging portfolio.

Expansion in the Philippines

Fischer’s international footprint expanded further through its partner Time Medical, with the inauguration of the Province of Bulacan’s first locally funded MRI facility in the Philippines, improving access to advanced diagnostic imaging services in the region.

Diagnostic Imaging Innovation in India

The company continued to expand its MRI portfolio with several key installations and product launches:

• Launch of a High-Resolution Open MRI system at Sunray Scans, Chennai.
• Installation of the PICA 0.35T Open MRI system at STNM Hospital, Sikkim.
• Introduction of the VEGA low-field Time-of-Flight MRI platform designed specifically for brain aneurysm imaging.
• Successful rollout of next-generation 1.5T MRI platforms under the MICA series.

Leadership Commentary

Commenting on the performance, Mr. Ravindran Govindan, Chairman, Fischer Medical Ventures Limited, said:

“FY26 was a landmark year for Fischer Medical Ventures, marked by significant progress across our operational, technological, and financial objectives. The strong growth in profitability demonstrates the scalability of our business model, improved product realization, and increasing acceptance of Fischer’s technologies across domestic and international markets.

India’s MedTech and diagnostic imaging sector is undergoing a transformational phase, supported by government initiatives focused on indigenous manufacturing, preventive healthcare, digital transformation, and AI-enabled clinical solutions. Fischer is strategically positioned to capitalize on these opportunities through our expanding portfolio of MRI systems, AI-powered diagnostics, and advanced healthcare technologies.

With a growing presence across Southeast Asia, continued product innovation, and strong customer adoption, we remain confident in sustaining our growth trajectory and creating long-term value for patients, healthcare providers, and shareholders.”

Additional Strategic Developments

Fischer Medical Ventures also achieved several noteworthy milestones during the year:

• Advanced development of the DRIS-iMRI Medharanya project in partnership with renowned neurosurgeon Dr. Iype Cherian for intra-operative MRI imaging applications.
• Recognition as the first-ever Industry Partner of the World Federation of Neurosurgical Societies (WFNS) Innovation and Technological Committee.
• Significant regulatory progress for Nanomedic’s SpinCare® technology, including successful completion of Phase 1 MDR/MDD audits, with Phase 2 audits scheduled for October 2025 and anticipated FDA filing in Q2 FY27.
• Strategic collaborations and participation at IRIA 2026, including partnerships with QUIN to advance diagnostic imaging innovation.

With strong momentum across diagnostic imaging, AI-enabled healthcare solutions, MRI technologies, and international market expansion, Fischer Medical Ventures remains well-positioned to benefit from accelerating healthcare investments across Asia and emerging markets.

The company expects continued growth driven by rising demand for affordable diagnostic technologies, government healthcare modernization initiatives, expanding tuberculosis screening programs, and increasing adoption of advanced imaging platforms worldwide.